FLT3 and acute myeloid leukemia: In this setting, we previously demonstrated that G-CSF treatment of a patient with t(8;21) AML led to complete remission.56 Moreover, the combined inhibition of miR-128a and miR-155 could be evaluated as a therapeutic option in high -isk AML patients harboring FLT3 mutation.